The phase III FOCUS clinical trial of Kyprolis in multiple myeloma did not meet its primary endpoint of improving overall survival.
A report from an international working group of researchers suggests that the process of evaluating human papillomavirus vaccines can be significantly shortened.
Genomic analyses of tissues from mantle cell lymphoma patients helped researchers explain two types of drug resistance and ways to overcome them in the clinic.
A phase III trial of Nexavar tablets in patients with advanced breast cancer did not meet its primary endpoint of extending progression-free survival.
Researchers with The Cancer Genome Atlas Network found that stomach cancers fall into four distinct molecular subtypes.
A phase III trial of Arzerra as a maintenance therapy for chronic lymphocytic leukemia met its primary endpoint of extending progression-free survival at an interim analysis.
FDA approved Zydelig (idelalisib) tablets for the treatment of three B-cell blood cancers.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase II study by the University of Florida Proton Therapy Institute shows that the use of proton therapy following chemotherapy in 15 patients with Hodgkin lymphoma has a success rate similar to the conventional treatments with a reduction of radiation outside of the target area, potentially reducing the risk of late effects caused by radiation.
An NCI study found that a negative HPV screening test result is a better predictor of low cervical cancer risk than a negative Pap test.
